Global Cardiac Mapping Market has been forecasted by Knowledge Sourcing Intelligence to grow at a CAGR of 9.46% in order for it to attain an estimated market value of US$1,527.102 million by 2025 from the market value of US$887.841 million that has been estimated for 2019. Such a healthy forecasted growth of the market primarily stems from factors that constitute aspects like the rising incidences of Wolff-Parkinson-White Syndrome, atrioventricular nodal reentry tachycardia, atrial flutter, and atrial fibrillation; as well as the constant evolution of instruments pertaining to cardiac mapping; the need for understanding the several aspects of the mechanisms underlying the variety of arrhythmias albeit their thorough investigation during the past decade. With regards to the need for understanding the underlying mechanisms, it is important to note that it still not known why the right ventricular outflow tract (RVOT)is the preferential site of origin of these arrhythmias. Further as noted by the National Health Service (NHS), of UK Atrial fibrillations is common in people who are suffering from other heart conditions Viz. pericarditis, high blood pressure (hypertension), heart valve disease, congenital heart disease, cardiomyopathyas well as atherosclerosis, thereby in a certain manner contributing to the high rate investment in R&D of products related which falls under the purview of cardiac mapping market.
Additionally, atrial fibrillation has also been associated with other medical conditions that comprise pulmonary embolism, pneumonia, overactive thyroid gland, lung cancer, diabetes, chronic obstructive pulmonary disease (COPD), carbon monoxide poisoning, and asthma. It is also important to note that globally, there were an estimated 2.1 million lung cancer cases in 2018. Further, the incidences of Wolff-Parkinson-White syndrome if accompanied by atrial fibrillation can require the patients to undergo Techniques and treatments that can help prevent episodes that constitute catheter ablation, among others which are further poised to contribute to the cardiac mapping market growth.
Moreover, the understanding of the anatomy through technological means to further the prospects of diagnosis, detection, and treatment among others necessities a thorough understanding and constant evolution of a variety of parameters of markets such as this one where technology and its application play an instrumental role. To this end, the following is being mentioned to provide a brief window to multifarious aspects that have been accompanied by other factors that have led to the development of the cardiac mapping market and its anticipated growth in the next few years.
Further, Electroanatomical mapping (EAM) which provides 3-4 dimensional views of cardiac structures that can be merged with cardiac CT (CCT) before the ablation procedure are carried out to provide detailed anatomy and structure of the target cardiac chamber have been known to support a variety of mapping modalities. For instance, activation mapping, which was the first method used for cardiac mapping during sinus rhythm and a variety of cardiac arrhythmias using hand?held probes to register the activation maps remains the cornerstone of cardiac mapping but the technique and has reportedly witnessed substantial enhancements. Initially, single hand?held probes were used to create isochronal maps. Further, this High?resolution activation mapping can identify areas of slow conduction that participate in arrhythmia mechanisms. Similarly, propagation mapping is useful to delineate areas of very slow conduction that participate in critical reentry pathways such as atrial flutter, scar?related ventricular tachycardia, atrioventricular nodal reentrant tachycardia, and slow pathway mapping. The capability to extend the understanding of AF through the means of activation mapping albeit being limited has the substantial potential of improving with the employment of multipolar electrode catheters and automated signal processing which is expected to drive the growth of the cardiac mapping market.
Moreover, another mapping modality called voltage mapping has been reportedly used to target areas for catheter ablation in a variety of different arrhythmias, especially in AF and ventricular tachycardia. Besides, another technique that has not been typically used for mapping of AF is pace mapping. It has been known to be employed in cases of premature ventricular complexes, or atrial tachycardias where the spontaneous arrhythmia is non?inducible or rarely inducible. Pace mapping for ventricular tachycardia (VT) and frequent symptomatic premature ventricular complexes (PVCs) is reportedly carried out by pacing from sites in the ventricles to entirely replicate the 12lead QRS morphology of the VT that has been recorded on a standard ECG during the clinical arrhythmia or has been induced in the EP laboratory. In this manner, the site of origin of a focal VT and the critical isthmus of a reentrant VT are indicated. Further, Entrainment, or continuous resetting of an ongoing reentrant arrhythmia by overdrive pacing, has been used for decades for diagnosing the mechanism of arrhythmias (in separating focal from reentrant mechanisms, as well as distinguishing among reentrant arrhythmias). Entrainment mapping has been employed to determine the location of sites from which the recordings originated are in relation to a circuit from the behavior of electrograms after stimulation has ceased. A recent example is an announcement by Acutus Medical, Inc. of the FDA 510(k) clearance of its second-generation AcQMap 3D imaging and mapping catheter that reportedly features, among others, a combination of 48 ultrasound transducers to create an anatomical geometry and has been developed based on the predecessor, improving handling and deliverability.
Since the publication of the seminal report by Haissaguerre and colleagues in 1998, there has been a considerable shift in perception of the pathophysiology and management of patients with atrial fibrillation (AF). Presently, AF ablation is acknowledged as an integral and important part of management as a class I level of evidence A in patients with paroxysmal AF, particularly in those refractories to antiarrhythmic therapy. Moreover, the superiority of catheter ablation over medical rate control has been reaffirmed by, randomized controlled trials. Additionally, it is important to acknowledge that mapping and imaging technology is presently at an unparalleled juncture. Currently, the broadening of comprehension and treatment of arrhythmias has been facilitated by the huge armamentarium of mapping and ablation catheters and imaging technologies. Thus, the factors and developments impacting the healthcare industry are fundamental to the growth of the global cardiac mapping market during the forecast period.